Tumor‐induced osteomalacia (TIO) is the most prevalent form of acquired hypophosphatemic osteomalacia.1 In nature, TIO is a paraneoplastic syndrome; the majority of cases are caused by tumors with excess production and secretion of fibroblast growth factor 23 (FGF23), the majority of which are classified as a phosphaturic mesenchymal tumor (PMT) or a PMT, mixed connective tissue variant (PMTMCT).2 FGF23 plays a key role in the regulation of phosphorus homeostasis. This evidence concerns the gene FGF23 and mesenchymal cell neoplasm.